

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/481,572	01/11/2000	JACQUELINE J. SHAN	P8061-9013	5800
7:	590 01/11/2002			
ARENT FOX KINTNER PLOTKIN & KAHN PLLC			EXAMINER	
1050 CONNECTICUT AVENUE NW SUITE 600			MELLER, MICHAEL V	
WASHINGTO	N, DC 20036-5339		ART UNIT PAPER NUMBER	

1651 DATE MAILED: 01/11/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
Advisory Action	09/481,572	SHAN ET AL.	
	Examiner	Art Unit	
	Michael V. Meller	1651	÷
Th MAILING DATE of this communication app	ears on the cover sheet with the o	correspondence add	lress
THE REPLY FILED 21 December 2001 FAILS TO PLATherefore, further action by the applicant is required to a final rejection under 37 CFR 1.113 may only be either: (condition for allowance; (2) a timely filed Notice of Appearamentation (RCE) in compliance with 37 CFR 1.114.	void abandonment of this applicall) a timely filed amendment which all (with appeal fee); or (3) a timel	ation. A proper repl h places the applica	y to a ation in
PERIOD FOR R	EPLY [check either a) or b)]		
a) The period for reply expiresmonths from the maili b) The period for reply expires on: (1) the mailing date of this no event, however, will the statutory period for reply expire ONLY CHECK THIS BOX WHEN THE FIRST REPLY WA 706.07(f).	Advisory Action, or (2) the date set forth later than SIX MONTHS from the mailin S FILED WITHIN TWO MONTHS OF TH	g date of the final rejecti HE FINAL REJECTION.	ion. See MPEP
Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the period fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of (2) as set forth in (b) above, if checked. Any reply received by the Off timely filed, may reduce any earned patent term adjustment. See 37	of extension and the corresponding amo the shortened statutory period for reply ice later than three months after the mai	ount of the fee. The apportunity or the final originally set in the final	ropriate extension Office action; or
1. A Notice of Appeal was filed on <u>21 December 2001</u> 37 CFR 1.192(a), or any extension thereof (37 CF			t forth in
2. The proposed amendment(s) will not be entered by	ecause:		
(a) \(\subseteq \) they raise new issues that would require furth	er consideration and/or search (see NOTE below);	
(b) \(\sum \) they raise the issue of new matter (see Note	below);		
(c) they are not deemed to place the application issues for appeal; and/or	in better form for appeal by mate	rially reducing or sir	mplifying the
(d) they present additional claims without cance	ling a corresponding number of f	inally rejected claim	s.
NOTE: <u>See Continuation Sheet</u> .			
3. Applicant's reply has overcome the following reject	tion(s):		
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).		-	
5. The a) affidavit, b) exhibit or c) request fo application in condition for allowance because: Se	r reconsideration has been consi <u>se Continuation Sheet</u> .	dered but does NO	T place the
6. The affidavit or exhibit will NOT be considered becaused by the Examiner in the final rejection.	cause it is not directed SOLELY t	o issues which were	e newly
7. For purposes of Appeal, the proposed amendmen explanation of how the new or amended claims w	t(s) a)⊠ will not be entered or b) ould be rejected is provided belo	☐ will be entered a w or appended.	and an
The status of the claim(s) is (or will be) as follows:			
Claim(s) allowed: None.			
Claim(s) objected to:			
Claim(s) rejected: 1-17 and 22.			
Claim(s) withdrawn from consideration:			
8. The proposed drawing correction filed on is	a) approved or b) disapp	roved by the Exami	ner.
9. Note the attached Information Disclosure Stateme	nt(s)(PTO-1449) Paper No(s)		
10. ☐ Other:			
		,	
		•	
U.S. Patent and Trademark Office			

Continuation of 2. NOTE: the phrase, "Hyperfour perforatum is the only active agent administract according to the mathod", raises new issues and the issue of new matter.

Continuation of 5, does NOT place the application in condition for allowance because: the claims still read on anyone taking the Hypericum perforatum composition. The claims do not "qualify the patient" to be treated, thus EP-647756 still reads on the claimed invention.

> DAVID M. NAFF PRIMARY EXAMINER ART UNIT 1255